Diverticulitis Drugs Market Size & Share, by Drug Type {Antibiotics (Metronidazole, Amoxicillin, Moxifloxacin), Dietary Fiber}; Route of Administration (Oral, Intravenous); Distribution Channel (Online, Offline); End-user (Specialty Clinics, Hospitals, Research Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2029

  • Report ID: 3054
  • Published Date: Feb 10, 2023
  • Report Format: PDF, PPT

Global Diverticulitis Drugs Market Highlights over 2020-2029

The global diverticulitis drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2021-2029. This growth can be attributed to the growing prevalence of obesity, rising old age population, and the inclination of youth towards an unhealthy lifestyle. Moreover, eating excessive red meat, and lack of fiber in diet can also lead to diverticulitis. According to a report by the World Health Organization, more than 2 billion people in the world do not have access to a balanced diet. In another report of the WHO, it is stated that around 1.9 billion adults were overweight and 650 million were obese, in the year 2016. In fact, at present, there are more overweight individuals than underweight, globally. This is estimated to elevate the prevalence of diverticulitis, which in turn, is estimated to boost the market growth. Additionally, factors such as government initiatives and support to treat the disease, rising demand for advanced treatment options, and growing market players offering newer products, are anticipated to drive the growth of the market over the coming years. CLICK TO DOWNLOAD SAMPLE REPORT


The global diverticulitis drugs market is segmented by end-user into specialty clinics, hospitals, research centers, and others. Among these, the hospitals segment is anticipated to hold the largest market share over the forecast period on the back of symptoms and complications associated with the disease. Its symptoms include cramps on the left side of the abdomen which goes away after passing gas or stool, abdominal pain, fever, diarrhea, bloating, bleeding from rectum, bright red blood in stool, and others, which often need immediate attention from medical staff.

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Diverticulitis Drugs Market Regional Synopsis

On the basis of regional analysis, the global diverticulitis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region.

The market in the North America is anticipated to hold the largest market share over the forecast period on account of rising obese population, and availability of advanced treatment options. Additionally, the growing cases of various gastrointestinal diseases, including diverticulitis, is estimated to boost the market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in the United States, about 58% of the individuals above 60 years of age have diverticulosis and about 5% of people with diverticulosis tends to develop diverticulitis. According to another report by the NIDDK, around 200,000 individuals are hospitalized for diverticulitis each year in the United States.

The market in the Asia Pacific is anticipated to grow at the highest CAGR over the forecast period owing to the growing number of patients, rising awareness among the individuals regarding health, availability of new treatment methods, improvement in the standard of living, and rapidly improving health care infrastructure.


The global diverticulitis drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis.
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis.
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis.
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Market Segmentation

Our in-depth analysis of the global diverticulitis drugs market includes the following segments:

By Drug Type

  • Antibiotics
    • Metronidazole
    • Amoxicillin
    • Moxifloxacin
    • Others
  • Dietary Fiber
  • Others

By Route of Administration

  • Oral
  • Injection

By Distribution Channel

  • Online
  • Offline

By End-User

  • Specialty Clinics
  • Hospitals
  • Research Centers
  • Others

Growth Drivers

  • Increasing Trend of Sedentary Lifestyle and Unhealthy Diet
  • Increasing Global Geriatric Population


  • Lack of Awareness among People Regarding the Disease
  • Stringent Regulations of the Government Regarding the Approval of Medicines

Top Featured Companies Dominating the Market

  • Emmaus Life Sciences, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Synergy Pharma
  • Abbott Laboratories
  • GlaxoSmithKline plc
  •  Ardelyx, Inc.
  • Gilead Sciences, Inc.
  • Trumac Healthcare
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Takeda Pharmaceutical Company Limited



In the News

  • January 29, 2020: Emmaus Life Sciences, Inc. has announced the preliminary results observed in the first patient in the company’s phase 1 study of diverticulosis treatment. The results were satisfactory and the company intends to continue the research and development process for novel drugs to treat diverticulitis
  • May 28, 2020: Hikma Pharmaceuticals PLC launched Dicyclomine Hydrochloride Oral Solution for the treatment of various inflammatory bowel diseases, including diverticulosis.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3054
  • Published Date: Feb 10, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of gastrointestinal problems backed by unhealthy diet, lifestyle diseases, and obesity, is the major factor driving the market growth.

The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2021-2029.

Lack of awareness about the seriousness of this problem among people is the major factor estimated to hamper the market growth.

The market in North America will provide the highest growth opportunities for the market during the forecast period on the back of efficient healthcare sector and growing medical R&D activities.

The major players in the market are Abbott Laboratories, Pfizer Inc., GlaxoSmithKline plc, Ardelyx, Inc., Gilead Sciences, Inc., Trumac Healthcare, Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, route of administration, distribution channel, end-user, and by region.

The hospital segment is anticipated to hold the largest market size during the forecast period on the back of various complications in this disease, which might require immediate attention.

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying